QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:IBRX

ImmunityBio - IBRX Stock Forecast, Price & News

$4.33
0.00 (0.00%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.25
▼
$4.51
50-Day Range
$3.78
▼
$6.77
52-Week Range
$2.60
▼
$7.85
Volume
1.64 million shs
Average Volume
1.78 million shs
Market Capitalization
$1.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

ImmunityBio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
107.9% Upside
$9.00 Price Target
Short Interest
Bearish
27.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.00) to ($0.96) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars

Medical Sector

853rd out of 1,027 stocks

Biological Products, Except Diagnostic Industry

137th out of 169 stocks

See Top Rated MarketRank™ Stocks Here
IBRX stock logo

About ImmunityBio (NASDAQ:IBRX) Stock

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Receive IBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter.

IBRX Stock News Headlines

February 2, 2023 | americanbankingnews.com
ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.2%
January 19, 2023 | finance.yahoo.com
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
February 6, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
December 12, 2022 | finance.yahoo.com
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
November 17, 2022 | finance.yahoo.com
ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference
October 27, 2022 | finance.yahoo.com
ImmunityBio to Participate in the Jefferies London Healthcare Conference
October 19, 2022 | finance.yahoo.com
15 Best Drug Stocks to Buy Now - Yahoo Finance
October 17, 2022 | seekingalpha.com
ImmunityBio: PDUFA Pending (NASDAQ:IBRX) - Seeking Alpha
February 6, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
October 11, 2022 | finance.yahoo.com
IMMUSE™ Interactive Masterclass Explores Immune System Balance To Build Lifelong Resilience - Yahoo Finance
September 15, 2022 | seekingalpha.com
HeartBeam, NeuroBo top healthcare gainers; Shuttle, Omeros lead losers' pack - Seeking Alpha
September 14, 2022 | latimes.com
Experimental COVID-19 vaccine may outsmart future coronavirus variants - Los Angeles Times
September 12, 2022 | nasdaq.com
IBRX Makes Bullish Cross Above Critical Moving Average
September 7, 2022 | bloomberg.com
Pandemic Readiness Lobby Draws In Biotech, Government Members - Bloomberg
September 4, 2022 | nasdaq.com
ImmunityBio, Inc.'s (NASDAQ:IBRX) most bullish insider, Top Key Executive Patrick Soon-Shiong must be pleased with the recent 4.9% gain
August 10, 2022 | nasdaq.com
Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates - Nasdaq
August 4, 2022 | nasdaq.com
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates - Nasdaq
August 3, 2022 | benzinga.com
ImmunityBio shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating a - Benzinga
July 29, 2022 | benzinga.com
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In K - Benzinga
July 28, 2022 | businesswire.com
ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ - Business Wire
July 28, 2022 | finance.yahoo.com
ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
July 27, 2022 | finance.yahoo.com
Fauci on needing a second generation of COVID vaccines: 'We have multiple variants of concern ... And it's getting more complicated' - Yahoo Finance
June 7, 2022 | finance.yahoo.com
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting - Yahoo Finance
June 6, 2022 | businesswire.com
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting - Business Wire
June 6, 2022 | finance.yahoo.com
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
June 2, 2022 | seekingalpha.com
ImmunityBio: Shifting Gears After Long-Awaited BLA Submission (NASDAQ:IBRX) - Seeking Alpha
May 23, 2022 | businesswire.com
ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ - Business Wire
See More Headlines
Receive IBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter.

IBRX Company Calendar

Last Earnings
11/08/2022
Today
2/06/2023
Next Earnings (Estimated)
2/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IBRX
CUSIP
N/A
CIK
1326110
Web
immunitybio.com
Phone
(858) 633-0300
Fax
N/A
Employees
587
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+107.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-346,790,000.00
Net Margins
-71,743.44%
Pretax Margin
-71,911.30%
Return on Equity
N/A
Return on Assets
-104.67%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.02
Quick Ratio
2.02

Sales & Book Value

Annual Sales
$930,000.00
Price / Sales
1,863.76
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.61) per share
Price / Book
-7.10

Miscellaneous

Outstanding Shares
400,300,000
Free Float
81,142,000
Market Cap
$1.73 billion
Optionable
Optionable
Beta
1.56

Key Executives

  • Patrick Soon-Shiong
    Executive Chairman & Global Chief Medical Officer
  • Richard AdcockRichard Adcock
    President, Chief Executive Officer & Director
  • Leonard S. Sender
    Chief Operating Officer
  • David Sachs
    Chief Financial Officer
  • John H. Lee
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













IBRX Stock - Frequently Asked Questions

Should I buy or sell ImmunityBio stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunityBio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IBRX shares.
View IBRX analyst ratings or view top-rated stocks.

What is ImmunityBio's stock price forecast for 2023?

1 Wall Street analysts have issued 12 month price objectives for ImmunityBio's shares. Their IBRX share price forecasts range from $8.00 to $10.00. On average, they predict the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 100.4% from the stock's current price.
View analysts price targets for IBRX or view top-rated stocks among Wall Street analysts.

How have IBRX shares performed in 2023?

ImmunityBio's stock was trading at $5.07 at the beginning of 2023. Since then, IBRX stock has decreased by 11.4% and is now trading at $4.49.
View the best growth stocks for 2023 here.

When is ImmunityBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our IBRX earnings forecast.

How were ImmunityBio's earnings last quarter?

ImmunityBio, Inc. (NASDAQ:IBRX) posted its earnings results on Tuesday, November, 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.05. The company earned $0.12 million during the quarter, compared to the consensus estimate of $0.03 million.

What is ImmunityBio's stock symbol?

ImmunityBio trades on the NASDAQ under the ticker symbol "IBRX."

Who are ImmunityBio's major shareholders?

ImmunityBio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.00%), Simplex Trading LLC (0.00%), Zurcher Kantonalbank Zurich Cantonalbank (0.00%), SG Americas Securities LLC (0.00%), Mayflower Financial Advisors LLC (0.00%) and Mayflower Financial Advisors LLC (0.00%). Insiders that own company stock include Barry J Simon, Cheryl Cohen and Richard Adcock.
View institutional ownership trends.

How do I buy shares of ImmunityBio?

Shares of IBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunityBio's stock price today?

One share of IBRX stock can currently be purchased for approximately $4.49.

How much money does ImmunityBio make?

ImmunityBio (NASDAQ:IBRX) has a market capitalization of $1.80 billion and generates $930,000.00 in revenue each year.

How many employees does ImmunityBio have?

The company employs 587 workers across the globe.

How can I contact ImmunityBio?

ImmunityBio's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The official website for the company is immunitybio.com. The company can be reached via phone at (858) 633-0300 or via email at investors@nantkwest.com.

This page (NASDAQ:IBRX) was last updated on 2/6/2023 by MarketBeat.com Staff